High-frequency actionable pathogenic exome variants in an average-risk cohort

Cold Spring Harbor Molecular Case Studies

Volumn 4, Issue 6, 2018, Pages

  Rego, Shannon ^a   Dagan Rosenfeld, Orit ^a   Zhou, Wenyu ^a   Reza Sailani, M ^a   Limcaoco, Patricia ^a   Colbert, Elizabeth ^a   Avina, Monika ^a   Wheeler, Jessica ^a   Craig, Colleen ^a   Salins, Denis ^a   Röst, Hannes L ^a   Dunn, Jessilyn ^a,b   McLaughlin, Tracey ^a   Steinmetz, Lars M ^a,c   Bernstein, Jonathan A ^a   Snyder, Michael P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLELE; APOE E4 GENE; ARTICLE; COHORT ANALYSIS; EXOME; FEMALE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; RISK FACTOR; CAUCASIAN; ETHICS; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIATION; GENETICS; GENOMICS; GENOTYPE; INCIDENTAL FINDING; NORMAL HUMAN; PHENOTYPE; PROCEDURES; WHOLE EXOME SEQUENCING;

ADULT; ALLELES; COHORT STUDIES; DATABASES, GENETIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXOME; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GENOMICS; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; INCIDENTAL FINDINGS; MALE; PHENOTYPE; WHOLE EXOME SEQUENCING;

EID: 85058744137     PISSN: None     EISSN: 23732873     Source Type: Journal    
DOI: 10.1101/mcs.a003178     Document Type: Article

References (114)

1. Abdulhadi-Atwan M, Bushman J, Tornovsky-Babaey S, Perry A, Abu-Libdeh A, Glaser B, Shyng SL, Zangen DH. 2008. Novel de novo mutation in sulfonylurea receptor 1 presenting as hyperinsulinism in infancy followed by overt diabetes in early adolescence. Diabetes 57: 1935-1940.
2. Adams MC, Evans JP, Henderson GE, Berg JS. 2016. The promise and peril of genomic screening in the general population. Genet Med 18: 593-599.
3. Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, Fahn S, Dorovski T, Chung WK, Pauciulo M, et al. 2014. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 71: 752-757.
4. Amendola LM, Dorschner MO, Robertson PD, Salama JS, Hart R, Shirts BH, Murray ML, Tokita MJ, Gallego CJ, Kim DS, et al. 2015. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Res 25: 305-315.
5. Bacon S, Kyithar MP, Rizvi SR, Donnelly E, McCarthy A, Burke M, Colclough K, Ellard S, Byrne MM. 2015. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. Diabet Med 33: 976-984.
6. Baier LJ, Muller YL, Remedi MS, Traurig M, Piaggi P, Wiessner G, Huang K, Stacy A, Kobes S, Krakoff J, et al. 2015. ABCC8 R1420H loss-of-function variant in a Southwest American Indian community: association with increased birth weight and doubled risk of type 2 diabetes. Diabetes 64: 4322-4332.
7. ATP channel gene mutation analysis to the clinical management of children with congenital hyperinsulinism. Eur J Endocrinol 164: 733-740.
8. Banno F, Kita T, Fernández JA, Yanamoto H, Tashima Y, Kokame K, Griffin JH, Miyata T. 2015. Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation. Blood 126: 2247-2253.
9. Bazalová Z, Rypácková B, Broz J, Brunerová L, Polák J, Rusavý Z, Treslová L, Andel M. 2010. Three novel mutations in MODY and its phenotype in three different Czech families. Diabetes Res Clin Pract 88: 132-138.
10. Bellanné-Chantelot C, Carette C, Riveline JP, Valéro R, Gautier JF, Larger E, Reznik Y, Ducluzeau PH, Sola A, Hartemann-Heurtier A, et al. 2008. The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes 57: 503-508.
11. Bemelmans SA, Tromp K, Bunnik EM, Milne RJ, Badger S, Brayne C, Schermer MH, Richard E. 2016. Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. Alzheimers Res Ther 8: 46.
12. Benn DE, Croxson MS, Tucker K, Bambach CP, Richardson AL, Delbridge L, Pullan PT, Hammond J, Marsh DJ, Robinson BG. 2003. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromo-cytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocyto-mas. Oncogene 22: 1358-1364.
13. Bertram L, Lill CM, Tanzi RE. 2010. The genetics of Alzheimer disease: back to the future. Neuron 68: 270-281.
14. Boursi B, Sella T, Liberman E, Shapira S, David M, Kazanov D, Arber N, Kraus S. 2013. The APC p.I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews. Eur J Cancer 49: 3680-3685.
15. + channel. Diabetes 61: 2585-2591.
16. ∗ 1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74: 1175-1182.
17. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Chen R, Lam HY, Miriami E, Karczewski KJ, Hariharan M, Dewey FE, et al. 2012. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148: 1293-1307.
18. Chen R, Shi L, Hakenberg J, Naughton B, Sklar P, Zhang J, Zhou H, Tian L, Prakash O, Lemire M, et al. 2016. Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nat Biotechnol 34: 531-538.
19. Clift KE, Halverson CM, Fiksdal AS, Kumbamu A, Sharp RR, McCormick JB. 2016. Patients' views on incidental findings from clinical exome sequencing. Appl Transl Genom 4: 38-43.
20. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
21. Costa A, Bescós M, Velho G, Chêvre J, Vidal J, Sesmilo G, Bellanné-Chantelot C, Froguel P, Casamitjana R, Rivera-Fillat F, et al. 2000. Genetic and clinical characterisation of maturity-onset diabetes of the young in Spanish families. Eur J Endocrinol 142: 380-386.
22. De Stefano V, Rossi E. 2013. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost 110: 697-705.
23. Dewey FE, Grove ME, Pan C, Goldstein BA, Bernstein JA, Chaib H, Merker JD, Goldfeder RL, Enns GM, David SP, et al. 2014. Clinical interpretation and implications of whole-genome sequencing. JAMA 311: 1035-1045.
24. Dewey FE, Grove ME, Priest JR, Waggott D, Batra P, Miller CL, Wheeler M, Zia A, Pan C, Karzcewski KJ, et al. 2015. Sequence to medical phenotypes: a framework for interpretation of human whole genome DNA sequence data. PLoS Genet 11: e1005496.
25. Dewey FE, Murray MF, Overton JD, Habegger L, Leader JB, Fetterolf SN, O'Dushlaine C, Van Hout CV, Staples J, Gonzaga-Jauregui C, et al. 2016. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science 354: aaf6814.
26. Dorschner MO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego CJ, Bennett RL, Jones KL, Tokita MJ, Bennett JT, et al. 2013. Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet 93: 631-640.
27. Font MA, Feliubadalo L, Estivill X, Nunes V, Golomb E, Kreiss Y, Pras E, Bisceglia L, d'Adamo AP, Zelante L, et al. 2001. Functional analysis of mutations in SLC7A9, and genotype-phenotype correlation in non-Type I cystinuria. Hum Mol Genet 10: 305-316.
28. Frayling IM, Beck NE, Ilyas M, Dove-Edwin I, Goodman P, Pack K, Bell JA, Williams CB, Hodgson SV, Thomas HJ, et al. 1998. The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. Proc Natl Acad Sci 95: 10722-10727.
29. Gambin T, Jhangiani SN, Below JE, Campbell IM, Wiszniewski W, Muzny DM, Staples J, Morrison AC, Bainbridge MN, Penney S, et al. 2015. Secondary findings and carrier test frequencies in a large multiethnic sample. Genome Med 7: 54.
30. Gardner DS, Tai ES. 2012. Clinical features and treatment of maturity onset diabetes of the young (MODY). Diabetes Metab Syndr Obes 5: 101-108.
31. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Kerlan V, Plouin PF, Rotig A, Jeunemaitre X. 2002. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 87: 4771-4774.
32. Gonzalez-Garay ML, McGuire AL, Pereira S, Caskey CT. 2013. Personalized genomic disease risk of volunteers. Proc Natl Acad Sci 110: 16957-16962.
33. Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, et al. 2009. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 361: 245-254.
34. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, Nussbaum RL, O'Daniel JM, Ormond KE, et al. 2013. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 15: 565-574.
35. Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, Fisher B, Spaneas L, Porath JD, Braun DA, et al. 2014. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26: 543-551.
36. Halperin A, Elstein D, Zimran A. 2006. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 36: 426-428.
37. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. 2005. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 33: D514-D517.
38. Hayakawa T, Morimoto A, Nozaki Y, Kashii Y, Aihara T, Maeda K, Momoi MY. 2011. Mesenteric venous thrombosis in a child with type 2 protein S deficiency. J Pediatr Hematol Oncol 33: 141-143.
39. Hayashi T, Nishioka J, Shigekiyo T, Saito S, Suzuki K. 1994. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood 83: 683-690.
40. Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V, Bronner M, Buisson M, Coulet F, Gaildrat P, et al. 2012. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat 33: 1228-1238.
41. Huang SS, Liu Y, Jing ZC, Wang XJ, Mao YM. 2016. Common genetic risk factors of venous thromboembolism in Western and Asian populations. Genet Mol Res 15: 15017644.
42. Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko HL, Rahier J, Vauhkonen I, Kere J, Laakso M, Ashcroft F, et al. 2000. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest 106: 897-906.
43. Huopio H, Otonkoski T, Vauhkonen I, Reimann F, Ashcroft FM, Laakso M. 2003. A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet 361: 301-307.
44. Ikejiri M, Wada H, Sakamoto Y, Ito N, Nishioka J, Nakatani K, Tsuji A, Yamada N, Nakamura M, Ito M, et al. 2010. The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. Int J Hematol 92: 302-305.
45. Jain A, Gandhi S, Koshy R, Scaria V. 2018. Incidental and clinically actionable genetic variants in 1005 whole exomes and genomes from Qatar. Mol Genet Genomics 293: 919-929.
46. Jamuar SS, Kuan JL, Brett M, Tiang Z, Tan WL, Lim JY, Liew WK, Javed A, Law HY, Tan ES, et al. 2016. Incidentalome from genomic sequencing: a barrier to personalized medicine? EBioMedicine 5: 211-216.
47. Jang MA, Lee SH, Kim N, Ki CS. 2015. Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes. Genet Med 17: 1007-1011.
48. Johnston JJ, Rubinstein WS, Facio FM, Ng D, Singh LN, Teer JK, Mullikin JC, Biesecker LG. 2012. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 91: 97-108.
49. Johnston JJ, Lewis KL, Ng D, Singh LN, Wynter J, Brewer C, Brooks BP, Brownell I, Candotti F, Gonsalves SG, et al. 2015. Individualized iterative phenotyping for genome-wide analysis of loss-of-function mutations. Am J Hum Genet 96: 913-925.
50. Jurgens J, Ling H, Hetrick K, Pugh E, Schiettecatte F, Doheny K, Hamosh A, Avramopoulos D, Valle D, Sobreira N. 2015. Assessment of incidental findings in 232 whole-exome sequences from the Baylor-Hopkins Center for Mendelian Genomics. Genet Med 17: 782-788.
51. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, Herman GE, Hufnagel SB, Klein TE, Korf BR, et al. 2017. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 19: 249-255.
52. Kapoor RR, Flanagan SE, James CT, McKiernan J, Thomas AM, Harmer SC, Shield JP, Tinker A, Ellard S, Hussain K. 2011. Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8/ KCNJ11 mutations. Diabetologia 54: 2575-2583.
53. Kim E, Rath EM, Tsang VH, Duff AP, Robinson BG, Church WB, Benn DE, Dwight T, Clifton-Bligh RJ. 2015. Structural and functional consequences of succinate dehydrogenase subunit B mutations. Endocr Relat Cancer 22: 387-397.
54. Kimura N, Takekoshi K, Horii A, Morimoto R, Imai T, Oki Y, Saito T, Midorikawa S, Arao T, Sugisawa C, et al. 2014. Clinicopathological study of SDHB mutation-related pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer 21: L13-L16.
55. Kimura R, Sakata T, Kokubo Y, Okamoto A, Okayama A, Tomoike H, Miyata T. 2006. Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers. J Thromb Haemost 4: 2010-2013.
56. Komine K, Shimodaira H, Takao M, Soeda H, Zhang X, Takahashi M, Ishioka C. 2015. Functional complemen-tation assay for 47 MUTYH variants in a MutY-disrupted Escherichia coli strain. Hum Mutat 36: 704-711.
57. Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostrer H, Giardiello FM, Hamilton SR, Hampel H, Markowitz A, Klimstra D, et al. 1997. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 17: 79-83.
58. Lam HY, Pan C, Clark MJ, Lacroute P, Chen R, Haraksingh R, O'Huallachain M, Gerstein MB, Kidd JM, Bustamante CD, et al. 2012. Detecting and annotating genetic variations using the HugeSeq pipeline. Nat Biotechnol 30: 226-229.
59. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott DR. 2014. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 42: D980-D985.
60. Lawrence L, Sincan M, Markello T, Adams DR, Gill F, Godfrey R, Golas G, Groden C, Landis D, Nehrebecky M, et al. 2014. The implications of familial incidental findings from exome sequencing: the NIH Undiagnosed Diseases Program experience. Genet Med 16: 741-750.
61. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, et al. 2016. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536: 285-291.
62. Lewis KL, Hooker GW, Connors PD, Hyams TC, Wright MF, Caldwell S, Biesecker LG, Biesecker BB. 2016. Participant use and communication of findings from exome sequencing: a mixed-methods study. Genet Med 18: 577-583.
63. Li D, Morales A, Gonzalez-Quintana J, Norton N, Siegfried JD, Hofmeyer M, Hershberger RE. 2010. Identification of novel mutations in RBM20 in patients with dilated cardiomyopathy. Clin Transl Sci 3: 90-97.
64. Liang J, Lin C, Hu F, Wang F, Zhu L, Yao X, Wang Y, Zhao Y. 2013. APC polymorphisms and the risk of colorectal neoplasia: a HuGE review and meta-analysis. Am J Epidemiol 177: 1169-1179.
65. Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, Bick D, Bottinger EP, Brilliant MH, Eng C, et al. 2013. Implementing genomic medicine in the clinic: the future is here. Genet Med 15: 258-267.
66. Masica DL, Karchin R. 2016. Towards increasing the clinical relevance of in silico methods to predict pathogenic missense variants. PLoS Comput Biol 12: e1004725.
67. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297-1303.
68. ∗ )1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31: 55-59.
69. Miyaki M, Iijima T, Yamaguchi T, Hishima T, Tamura K, Utsunomiya J, Mori T. 2005. Germline mutations of the MYH gene in Japanese patients with multiple colorectal adenomas. Mutat Res 578: 430-433.
70. Miyata T, Sato Y, Ishikawa J, Okada H, Takeshita S, Sakata T, Kokame K, Kimura R, Honda S, Kawasaki T, et al. 2009. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res 124: 14-18.
71. National Comprehensive Cancer Network. 2016. National Comprehensive Cancer Network. Colorectal Cancer Screening (Version 2.2016).
72. National Comprehensive Cancer Network. 2017. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 2.2017).
73. National Diabetes Statistics Report. 2014. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Centers for Disease Control and Prevention. U.S. Department of Health and Human Services, Atlanta, GA.
74. Neki R, Fujita T, Kokame K, Nakanishi I, Waguri M, Imayoshi Y, Suehara N, Ikeda T, Miyata T. 2011. Genetic analysis of patients with deep vein thrombosis during pregnancy and postpartum. Int J Hematol 94: 150-155.
75. Olschwang S, Blanché H, de Moncuit C, Thomas G. 2007. Similar colorectal cancer risk in patients with mono-allelic and biallelic mutations in the MYH gene identified in a population with adenomatous polyposis. Genet Test 11: 315-320.
76. Patwardhan A, Harris J, Leng N, Bartha G, Church DM, Luo S, Haudenschild C, Pratt M, Zook J, Salit M, et al. 2015. Achieving high-sensitivity for clinical applications using augmented exome sequencing. Genome Med 7: 71.
77. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. 2003. Genetic cause of hyperglycae-mia and response to treatment in diabetes. Lancet 362: 1275-1281.
78. Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, Hillemanns P, Christiansen H, Park-Simon TW, Dörk T. 2012. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One 7: e47993.
79. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. 2013. Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet 9: e1003709.
80. ATP channel mutations. J Clin Invest 118: 2877-2886.
81. Reuter MS, Walker S, Thiruvahindrapuram B, Whitney J, Cohn I, Sondheimer N, Yuen RKC, Trost B, Paton TA, Pereira SL, et al. 2018. The Personal Genome Project Canada: findings from whole genome sequences of the inaugural 56 participants. CMAJ 190: E126-E136.
82. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. 2015. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17: 405-424.
83. Ruggieri V, Pin E, Russo MT, Barone F, Degan P, Sanchez M, Quaia M, Minoprio A, Turco E, Mazzei F, et al. 2012. Loss of MUTYH function in human cells leads to accumulation of oxidative damage and genetic instability. Oncogene 32: 4500-4508.
84. Sanderson SC, Linderman MD, Suckiel SA, Zinberg R, Wasserstein M, Kasarskis A, Diaz GA, Schadt EE. 2017. Psychological and behavioural impact of returning personal results from whole-genome sequencing: the HealthSeq project. Eur J Hum Genet 25: 280-292.
85. Saxena N, Maio N, Crooks DR, Ricketts CJ, Yang Y, Wei MH, Fan TW, Lane AN, Sourbier C, Singh A, et al. 2016. SDHB-deficient cancers: the role of mutations that impair iron sulfur cluster delivery. J Natl Cancer Inst 108: djv287.
86. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. 2009. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 26: 437-441.
87. Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Rebbeck TR, Armstrong KA, Calzone K, Stopfer J, Seal S, Stratton MR, et al. 2002. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 20: 994-999.
88. Snider KE, Becker S, Boyajian L, Shyng SL, MacMullen C, Hughes N, Ganapathy K, Bhatti T, Stanley CA, Ganguly A. 2013. Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. J Clin Endocrinol Metab 98: E355-E363.
89. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN. 2003. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21: 577-581.
90. Stern HS, Viertelhausen S, Hunter AG, O'Rourke K, Cappelli M, Perras H, Serfas K, Blumenthall A, Dewar D, Baumann E, et al. 2001. APC I1307K increases risk of transition from polyp to colorectal carcinoma in Ashkenazi Jews. Gastroenterology 120: 392-400.
91. Stranks JL, Zimmermann AT, Radhakutty A, Vora P, Mann Mah P. 2016. Like mother like son? Variable expression and phenotype of an inactivating dominant ATP-binding cassette sub-family C member 8 (ABCC8) gene mutation within a single family. Vol 84. Annual Scientific Meeting of the Endocrine-Society-of-Australia, Conference paper.
92. Tabor HK, Auer PL, Jamal SM, Chong JX, Yu JH, Gordon AS, Graubert TA, O'Donnell CJ, Rich SS, Nickerson DA, et al. 2014. Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results. Am J Hum Genet 95: 183-193.
93. Tang CS, Dattani S, So MT, Cherny SS, Tam PKH, Sham PC, Garcia-Barcelo MM. 2018. Actionable secondary findings from whole-genome sequencing of 954 East Asians. Hum Genet 137: 31-37.
94. Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K, Rosenbaum H, Schiffmann R, Bembi B, Sidransky E. 2003. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79: 104-109.
95. The Integrative Human Microbiome Project. 2014. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16: 276-289.
96. The 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR, et al. 2015. A global reference for human genetic variation. Nature 526: 68-74.
97. Thornton PS, MacMullen C, Ganguly A, Ruchelli E, Steinkrauss L, Crane A, Aguilar-Bryan L, Stanley CA. 2003. Clinical and molecular characterization of a dominant form of congenital hyperinsulinism caused by a mutation in the high-affinity sulfonylurea receptor. Diabetes 52: 2403-2410.
98. Thusberg J, Olatubosun A, Vihinen M. 2011. Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat 32: 358-368.
99. Tonooka N, Tomura H, Takahashi Y, Onigata K, Kikuchi N, Horikawa Y, Mori M, Takeda J. 2002. High frequency of mutations in the HNF-1α gene in non-obese patients with diabetes of youth in Japanese and identification of a case of digenic inheritance. Diabetologia 45: 1709-1712.
100. Turkovic L, Gurrin LC, Bahlo M, Dite GS, Southey MC, Hopper JL. 2010. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age. BMC Cancer 10: 466.
101. Vail PJ, Morris B, van Kan A, Burdett BC, Moyes K, Theisen A, Kerr ID, Wenstrup RJ, Eggington JM. 2015. Comparison of locus-specific databases for BRCA1 and BRCA2 variants reveals disparity in variant classification within and among databases. J Community Genet 6: 351-359.
102. van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K. 2016. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 14: 1393-1403.
103. Vassy JL, Christensen KD, Schonman EF, Blout CL, Robinson JO, Krier JB, Diamond PM, Lebo M, Machini K, Azzariti DR, et al. 2017. The impact of whole-genome sequencing on the primary care and outcomes of healthy adult patients: a pilot randomized trial. Ann Intern Med 167: 159-169.
104. Vaxillaire M, Rouard M, Yamagata K, Oda N, Kaisaki PJ, Boriraj VV, Chevre JC, Boccio V, Cox RD, Lathrop GM, et al. 1997. Identification of nine novel mutations in the hepatocyte nuclear factor 1 alpha gene associated with maturity-onset diabetes of the young (MODY3). Hum Mol Genet 6: 583-586.
105. Vieira TC, Bergamin CS, Gurgel LC, Moisés RS. 2010. Hyperinsulinemic hypoglycemia evolving to gestational diabetes and diabetes mellitus in a family carrying the inactivating ABCC8 E1506K mutation. Pediatr Diabetes 11: 505-508.
106. Vreeswijk MP, Kraan JN, van der Klift HM, Vink GR, Cornelisse CJ, Wijnen JT, Bakker E, van Asperen CJ, Devilee P. 2008. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. Hum Mutat 30: 107-114.
107. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE. 2012. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92: 414-417.
108. Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, Clendenning M, Rosty C, MacInnis RJ, Giles GG, et al. 2014. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146: 1208-1211.e1201-1205.
109. Woodage T, King SM, Wacholder S, Hartge P, Struewing JP, McAdams M, Laken SJ, Tucker MA, Brody LC. 1998. The APC I1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet 20: 62-65.
110. Xiang HP, Geng XP, Ge WW, Li H. 2011. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. Eur J Cancer 47: 2546-2551.
111. Xue Y, Chen Y, Ayub Q, Huang N, Ball EV, Mort M, Phillips AD, Shaw K, Stenson PD, Cooper DN, et al. 2012. Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am J Hum Genet 91: 1022-1032.
112. Yamada S, Tomura H, Nishigori H, Sho K, Mabe H, Iwatani N, Takumi T, Kito Y, Moriya N, Muroya K, et al. 1999. Identification of mutations in the hepatocyte nuclear factor-1α gene in Japanese subjects with early-onset NIDDM and functional analysis of the mutant proteins. Diabetes 48: 645-648.
113. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, Ward P, Braxton A, Wang M, Buhay C, et al. 2014. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 312: 1870-1879.
114. Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, Sanft TB, Abu-Khalaf MM, Chung GG, Stein SM, et al. 2016. Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer 122: 1588-1597.